Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR240600C in Overactive Bladder or Urge Urinary Incontinence
NCT00174798Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of burapitant in overactive bladder (OAB) and urge urinary incontinence (UUI) (3 arms), sponsored by Sanofi. Primary endpoint: Change in bladder capacity as determined by cystometric parameters at 4 weeks. Started May 2005; status: completed.
02
Drugs
burapitant
03
Conditions
overactive bladder (OAB)urge urinary incontinence (UUI)
Beyond the preview
Go deeper on NCT00174798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174798.